Development of a Nomogram Model to Identify Appropriate Candidates from Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Based on the …
K Ren, H Ning, H Wu, F Wu, J Lyu - Clinical Genitourinary Cancer, 2024 - Elsevier
Background Although a survival benefit was observed in patients with metastatic renal cell
carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a lack of …
carcinoma (mRCC) who underwent cytoreductive nephrectomy (CN), there is a lack of …
Construction and validation of a novel prognostic nomogram for patients with metastatic renal cell carcinoma: a SEER-based study
Z Lu, W He, J Zhou, C Yang… - Journal of International …, 2022 - journals.sagepub.com
Objective We aimed to establish and validate nomograms to evaluate overall survival (OS)
and cancer-specific survival (CSS) in patients with metastatic renal cell carcinoma (MRCC) …
and cancer-specific survival (CSS) in patients with metastatic renal cell carcinoma (MRCC) …
[HTML][HTML] Five-year overall survival of patients with advanced bladder cancer in Kazakhstan: OSURK registry study
O Shatkovskaya, D Kaidarova… - American Journal of …, 2023 - ncbi.nlm.nih.gov
Background: The goals of the OSURK registry study were to assess 5-year overall survival
(OS) in patients with metastatic urothelial cancer diagnosed in 2017 in Kazakhstan and …
(OS) in patients with metastatic urothelial cancer diagnosed in 2017 in Kazakhstan and …
[HTML][HTML] Продолжительность жизни пациентов с метастатическим раком пищевода: российское многоцентровое регистровое исследование
ИВ Тимофеев, РА Зуков, ВВ Петкау… - Вопросы …, 2023 - cyberleninka.ru
Актуальность. В 2019 г. в России было диагностировано 8327 новых случаев рака
пищевода и зарегистрировано 5546 летальных исходов от этой опухоли. В настоящем …
пищевода и зарегистрировано 5546 летальных исходов от этой опухоли. В настоящем …
Analysis of outcomes of the first line systemic therapy in patients with solitary, single and multiple metastases of renal cell carcinoma
DV Semenov, D Vladimirovich… - Urology reports (St …, 2023 - journals.eco-vector.com
BACKGROUND: Currently there are practically no works in the literature to assess the
outcomes of systemic therapy in patients with solitary, single and multiple metastases of …
outcomes of systemic therapy in patients with solitary, single and multiple metastases of …
[HTML][HTML] Лекарственная терапия раннего рака почки в 2022 году: надежды и разочарования
ИВ Тимофеев - rosoncoweb.ru
Известно, что около 30% больных «ранним» светлоклеточным почечноклеточным
раком будут иметь прогрессирование болезни после стандартного хирургического …
раком будут иметь прогрессирование болезни после стандартного хирургического …